Cannara Biotech Declares DTC Eligibility to Enhance Access for U.S. Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 07 2025
0mins
Should l Buy ?
DTC Eligibility Announcement: Cannara Biotech's common shares are now eligible for electronic clearing and settlement in the U.S. through The Depository Trust Company, enhancing trading liquidity and access for U.S. investors.
Completion of Share Issuance: The company has issued 3,462,763 common shares to Olymbec Investments at $1.80 per share, totaling approximately $6.2 million to settle indebtedness related to its mega production facility in Valleyfield, Quebec.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
